8-K 1 urov-8k_20190319.htm 8-K urov-8k_20190319.htm










Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 19, 2019


Urovant Sciences Ltd.

(Exact name of Registrant as Specified in Its Charter)













(State or Other Jurisdiction

of Incorporation)


(Commission File Number)


(IRS Employer

Identification No.)






Suite 1, 3rd Floor

11-12 St. James’s Square

London SW1Y 4LB

United Kingdom




Not Applicable

(Address of Principal Executive Offices)




(Zip Code)


+44 203 318 9709

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 8.01. Other Events.


On March 19, 2019, Urovant Sciences, Ltd. (the “Company”) issued a press release announcing positive topline results from EMPOWUR, the Company’s international double-blind, placebo-controlled, multicenter Phase 3 clinical trial evaluating the efficacy and safety of vibegron 75mg in adults with symptoms of overactive bladder (“OAB”). Based on these data, the Company has stated that it intends to file an NDA by early 2020 for vibegron for the treatment of OAB. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.  


Following the announcement of the positive results of the EMPOWUR study, the Company is able to draw an additional $30,000,000 under the Company’s loan agreement with Hercules Capital, Inc. The Company has the discretion to draw this amount at any time through September 30, 2019.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits.















Press Release, dated March 19, 2019








Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




Urovant Sciences Ltd.






Dated: March 20, 2019









/s/ Christine G. Ocampo





Christine G. Ocampo





Principal Financial and Accounting Officer